Brief reportShort-term hemodynamic effect of a new oral PGI2 analogue, Beraprost, in primary and secondary pulmonary hypertension
References (13)
- et al.
The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species
Jpn J Pharmacol
(1988) - et al.
Role of prostacyclin in the treatment of primary pulmonary hypertension
Am J Cardiol
(1995) Medical treatment of primary pulmonary hypertension: a bridge to transplantation?
Am J Cardiol
(1995)- et al.
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
N Engl J Med
(1992) - et al.
Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary hypertension
Lancet
(1980) The place of prostacyclin in the clinical management of primary pulmonary hypertension
Am Rev Respir Dis
(1987)
Cited by (89)
Systemic sclerosis
2019, Genomic and Precision Medicine: Infectious and Inflammatory DiseaseSystemic Sclerosis
2013, Genomic and Personalized MedicineSystemic Sclerosis
2012, Genomic and Personalized MedicineRecent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension
2012, Journal of CardiologyCitation Excerpt :The clinical effects of iloprost are similar to epoprostenol and treprostinil, and superior to them with regard to inducible infections. Beraprost was the first oral drug for PAH [20,21], although its effects subside after half a year of use. Therefore, beraprost has only been approved and used in Japan.
Plasma Cyclic 3',5'-Adenosine Monophosphate in Patients With Elevated Pulmonary Pressure Due to Left-to-Right Shunt
2011, Canadian Journal of CardiologyTreatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs
2011, Respiratory MedicineCitation Excerpt :An oral formulation of treprostinil has been developed by United Therapeutics; however, this formulation has not yet been approved in the United States and is currently undergoing assessment in clinical trials.16,71–73 Similarly, beraprost (Procyclin®) has launched in Japan and Korea by Kaken Pharmaceuticals and is also undergoing assessment in the United States.74–85 The challenges of administration and adverse events associated with parenteral epoprostenol or treprostinil therapy (particularly the IV route) occasionally necessitate switching therapy, either from one analog to another or from prostaglandin analog therapy to another drug class, such as endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.
- 1
Dr. Saji's address is: Department of Pediatrics, Toho University, 6-11-1, Omorinisi, Ota-ku, Tokyo, 143, Japan.